Numerate, Inc.

SAN BRUNO, CA · CIK 0001439005 · Medtech · Acquired

Strategic consulting services combining AI and cybersecurity guidance

numerate.ai →
Grants
$675K
3 awards
Sector median: 1
Raised
$8.2M
1 Form D · Jun 2014
148 months since last filing
Contracts
$4.9M
1 award · Defense
#125 of 4531 in medtech
Patents
9
0 granted · 9 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal contractDepartment of Defense · Base Period$4,903,991
Private capital raisedForm D · SEC$8,240,487
Federal grantDepartment of Health and Human Services · Phase I · Peripherally restricted α2/δ-1 subunit ligands that modulate CaV channel gating as novel antiarrhythmic drugs$224,927
Federal grantDepartment of Health and Human Services · Phase I · EZH2 inhibitors as endoprosthetic device coatings that induce osteogenesis and promote implant osseointegration$224,878
Federal grantDepartment of Health and Human Services · Phase I · EZH inhibitors as endoprosthetic device coatings that induce osteogenesis and promote implant osseointegration$224,878
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
122Gate Scientific, Inc.$5.1M—
123AA PLASMA LLC$5.0M—
124DAXOR CORPORATION$4.9M—
125Numerate, Inc.$4.9M$8.2M
126DELTA DEVELOPMENT TEAM, INC$4.9M$1.3M
127B & W TEK INC$4.8M—
128ADVANCED LIFE TECHNOLOGIES, LLC$4.8M—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Bruce BoothDirector
  • John GriffinExecutive Officer
  • Steve HallDirector
  • Guido LanzaDirector · Executive Officer
  • Lucio LanzaDirector

Patents

USPTO · 0 granted of 9
  • Bicyclic Compounds Useful As GPR120 Modulatorsapplication
  • Monocyclic Compounds Useful As GPR120 Modulatorsapplication
  • Compounds Useful As GPR120 Modulatorsapplication
  • Compounds Useful As GPR120 Modulatorsapplication
  • Antibacterial Fluoroquinolone Analogsapplication
  • Anibacterial Fluoroquinolone Analogsapplication
  • Antibacterial Fluoroquinolone Analogsapplication
  • Antibacterial Fluoroquinolone Analogsapplication
  • Compositions And Treatments For Inhibiting Kinase And/or Hmg-coa Reductaseapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.